Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sevoflurane
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : National Institute of Arthritis and Musculoskeletal and Skin Diseases
Deal Size : $1.5 million
Deal Type : Funding
Details : The Phase II SBIR funding will be used to develop a formulation of VPX638 (sevoflurane) and to further characterize the anti-inflammatory and analgesic profile in animal disease models.
Brand Name : VPX638
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 11, 2020
Lead Product(s) : Sevoflurane
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : National Institute of Arthritis and Musculoskeletal and Skin Diseases
Deal Size : $1.5 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?